TBVAC2020: Advancing tuberculosis vaccines from discovery to clinical development

Nadia Rosalia Caccamo, Etienne Caron, Krista Van Meijgaarden, Natalie Nieuwenhuizen, Morten Ruhwald, Sung Jae Shin, Claudio Counoupas, Marta Romano, Nicolas Collin, Elena Stylianou, Jayne Sutherland, Ann Williams, Peter Andersen, Yvonne Perrie, Tom H. M. Ottenhoff, Ruedi Aebersold, Christophe Barnier-Quer, Pere-Joan Cardona, Dessi Marinova, Myrsini KaforouStephanie Kallert, Rachel Tanner, Mariateresa Coppola, Jeroen Maertzdorf, Nacho Aguilo, Genevieve Inchauspe, Dennis Christensen, Thomas Lindenstrom, Gerhard Walzl, Mei Mei Ho, Marc Baird, Hazel M. Dockrell, Hyejon Lee, Hermann Giresse Tima, Helen Fletcher, Frank A. W. Verreck, Ino Choi, Nick Drager, Brij Patel, Marie-Ange Demoitie, Stephane Leung Theung Long, François Spertini, Mei Mei Ho, Steven Smith, Marta Romano, Annemieke Geluk, Thomas Scriba, Cris Vilaplana, Iman Satti, Simone Joosten, Claus Aagaard, Nadia Caccamo, Martin Vordermeier, Daniel Pinschewer, Isabelle Vergne, Francoise Mascart, Frank Verreck, Alex Sigal, Olivier Neyrolles, Christophe Guilhot, Danilo Casimiro, Jelle Thole, Pierre Charneau, Annemieke Geluk, Jamie Triccas, Martine Gilleron, Helen Mcshane, Roberto Nisini, Steffen Stenger, Gennaro De Libero, Johan Grooten, Delia Goletti, Kris Huygen, Claire Anne Siegrist, Roland Brosch, Tom Ottenhoff, Antonio Peixoto, Peter Sander, Philip Hogarth, Camille Locht, Gregory Bancroft, Sally Sharpe, Warwick Britton, Helen Fletcher, Katalin Wilkinson, Dennis Christensen, Stephen Gordon, Robert Wilkinson, Michael Levin, Sang Nae Cho, Carlos Martin, January Weiner, Danielle Roordink, Simon Clark, Andre Loxton, Max Bastian, Stefan H. E. Kaufmann, Marta Romano

Risultato della ricerca: Article

19 Citazioni (Scopus)

Abstract

TBVAC2020 is a research project supported by the Horizon 2020 program of the European Commission (EC). It aims at the discovery and development of novel tuberculosis (TB) vaccines from preclinical research projects to early clinical assessment. The project builds on previous collaborations from 1998 onwards funded through the EC framework programs FP5, FP6, and FP7. It has succeeded in attracting new partners from outstanding laboratories from all over the world, now totaling 40 institutions. Next to the development of novel vaccines, TB biomarker development is also considered an important asset to facilitate rational vaccine selection and development. In addition, TBVAC2020 offers portfolio management that provides selection criteria for entry, gating, and priority settings of novel vaccines at an early developmental stage. The TBVAC2020 consortium coordinated by TBVI facilitates collaboration and early data sharing between partners with the common aim of working toward the development of an effective TB vaccine. Close links with funders and other consortia with shared interests further contribute to this goal.
Lingua originaleEnglish
pagine (da-a)1203-
Numero di pagine0
RivistaFrontiers in Immunology
Volume8
Stato di pubblicazionePublished - 2017

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology

Fingerprint Entra nei temi di ricerca di 'TBVAC2020: Advancing tuberculosis vaccines from discovery to clinical development'. Insieme formano una fingerprint unica.

  • Cita questo

    Caccamo, N. R., Caron, E., Meijgaarden, K. V., Nieuwenhuizen, N., Ruhwald, M., Shin, S. J., Counoupas, C., Romano, M., Collin, N., Stylianou, E., Sutherland, J., Williams, A., Andersen, P., Perrie, Y., Ottenhoff, T. H. M., Aebersold, R., Barnier-Quer, C., Cardona, P-J., Marinova, D., ... Romano, M. (2017). TBVAC2020: Advancing tuberculosis vaccines from discovery to clinical development. Frontiers in Immunology, 8, 1203-.